<DOC>
	<DOCNO>NCT00648830</DOCNO>
	<brief_summary>The objective study investigate bioequivalence Genpharm 's clarithromycin tablet follow single , oral 250 mg ( 1 x 250 mg ) dose compare Biaxin速 filmtab速 ( Abbott Laboratories USA ) administer fasted condition . Thirty-four ( 34 ) healthy , light- , non- ex-smoking subject least 18 year age randomize , four-period , two-treatment crossover bioequivalence study conduct Eric Sicard , M.D . Algorithme Pharma Inc. Montreal , Canada . Statistical analysis data reveals 90 % confidence interval within acceptable bioequivalent range 80 % 125 % natural log transform parameter AUCT , AUCI Cmax . This study demonstrate Genpharm 's clarithromycin 250 mg tablet bioequivalent Biaxin速 filmtab速 250 mg tablet ( Abbott Laboratories USA ) administer fasted condition .</brief_summary>
	<brief_title>Comparative Bioavailability Study Clarithromycin 250 mg Tablets</brief_title>
	<detailed_description />
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>Subjects meet follow criterion may include study : Availability volunteer entire study period willingness adhere protocol requirement evidence informed consent form ( ICF ) duly sign volunteer Males female age least 18 year body mass index ( BMI ) great equal 19 30 kg/m2 Clinical laboratory value within laboratory 's state normal range ; within range , must without clinical significance ( laboratory test present section 6.1.1.3 ) Healthy accord laboratory result physical examination Light , non ex smoker . Light smoker define someone smoking 10 cigarette less per day , ex smoker define someone completely stop smoke least 3 month Significant history hypersensitivity clarithromycin , erythromycin , macrolide antibacterial agent related product well severe hypersensitivity reaction ( like angioedema ) drug Presence history significant gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug know potentiate predispose undesired effect Presence history significant cardiovascular , pulmonary , hematologic , neurologic , psychiatric , endocrine , immunologic dermatologic disease Presence significant heart disease disorder accord ECG Females pregnant , lactate likely become pregnant study Females childbearing potential female take systemic contraceptive refuse use one acceptable contraceptive regimen ( describe section 5.4.9 ) throughout study Positive HCG beta serum pregnancy test study Maintenance therapy drug , significant history drug dependency alcohol abuse ( &gt; 3 unit alcohol per day , intake excessive alcohol , acute chronic ) Any clinically significant illness previous 28 day day 1 study Use enzymemodifying drug previous 28 day day 1 study ( barbiturate , corticosteroid , phenylhydantoins , etc . ) Participation another clinical trial previous 28 day day 1 study Donation 500 mL blood ( Canadian Blood Services , HemaQuebec , clinical study , etc . ) previous 56 day day 1 study Positive urine screen drug abuse ( drug list present section 6.1.1.4 ) Positive result HIV , HBsAg antiHCV test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>